Tag : HISTOLOGIC REMISSION

NEWS AND PERSPECTIVE

FDA approval of dupilumab as EoE treatment expands to include pediatric patients aged ≥1 year
Earlier this year, the United States (US) Food and Drug Administration (FDA) expanded the approval of dupilumab to include the treatment of eosinophilic esophagitis (EoE) in pediatric patients aged ≥1 year weighing at least 15 kg.